A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Eli Lilly and Company (NYSE:LLY), a leading pharmaceutical giant with a market capitalization of $724 billion, has been ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

The term "blue chip" originated from poker, where blue chips were the highest denomination of chips used in the game.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The Kokomo woman was prediabetic when she asked her doctor about Ozempic, the popular anti-diabetic drug. Usually prescribed ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

A woman who lost 64 pounds on a compounded form of the weight loss drug semaglutide, marketed as Wegovy and Ozempic, started ...

We recently compiled a list of the 8 Best Socially Responsible Stocks to Buy According to Hedge Funds. In this article, we ...

Kennedy is nominated to lead the Department of Health and Human Services, a position that would give him enormous control ...

Novo Nordisk said it had been able to ease some of the restrictions on the supply of starting doses of Wegovy, starting with the US, that were introduced to try to cope with the massive demand for ...

Wegovy is the first-to-market in a new class of highly effective weight-loss drugs. But analysts say that Novo’s supply constraints could allow rival Eli Lilly to get ahead, when it launches its ...